Cargando…
Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607112/ https://www.ncbi.nlm.nih.gov/pubmed/33178787 http://dx.doi.org/10.21037/atm-2020-79 |
| _version_ | 1783604578744270848 |
|---|---|
| author | Alqahtani, Saleh A. Colombo, Massimo |
| author_facet | Alqahtani, Saleh A. Colombo, Massimo |
| author_sort | Alqahtani, Saleh A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7607112 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76071122020-11-10 Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach Alqahtani, Saleh A. Colombo, Massimo Ann Transl Med Editorial Commentary AME Publishing Company 2020-10 /pmc/articles/PMC7607112/ /pubmed/33178787 http://dx.doi.org/10.21037/atm-2020-79 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Alqahtani, Saleh A. Colombo, Massimo Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach |
| title | Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach |
| title_full | Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach |
| title_fullStr | Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach |
| title_full_unstemmed | Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach |
| title_short | Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach |
| title_sort | multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607112/ https://www.ncbi.nlm.nih.gov/pubmed/33178787 http://dx.doi.org/10.21037/atm-2020-79 |
| work_keys_str_mv | AT alqahtanisaleha multikinaseinhibitorstotreathepatocellularcarcinomafailurestosorafenibtimehascomeforabetterapproach AT colombomassimo multikinaseinhibitorstotreathepatocellularcarcinomafailurestosorafenibtimehascomeforabetterapproach |